Clinical Trials Directory

Trials / Unknown

UnknownNCT03715699

Leflunomide Treatment for IgG4-RD

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
70 (estimated)
Sponsor
Peking Union Medical College Hospital · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study is an open-label randomized controlled trial aiming to investigate whether the efficacy and side effect of Leflunpomide plus glucocorticoid.

Conditions

Interventions

TypeNameDescription
DRUGPrednisonePrednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
DRUGPrednisone and LeflunomidePrednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months. Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months.

Timeline

Start date
2018-07-01
Primary completion
2020-12-31
Completion
2020-12-31
First posted
2018-10-23
Last updated
2018-10-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03715699. Inclusion in this directory is not an endorsement.

Leflunomide Treatment for IgG4-RD (NCT03715699) · Clinical Trials Directory